BC Innovations | Nov 22, 2019
Distillery Therapeutics

Dopamine receptor agonism for pulmonary fibrosis, liver fibrosis

DISEASE CATEGORY: Pulmonary; hepatic INDICATION: Pulmonary fibrosis; liver fibrosis Agonism of the dopamine receptor DRD1 could treat pulmonary and liver fibrosis. In cultures of lung fibroblasts derived from patients with idiopathic pulmonary fibrosis (IPF), a...
BC Innovations | Feb 28, 2018
Distillery Therapeutics


INDICATION: Parkinson’s disease (PD) Rat studies suggest non-catechol-based dopamine D1 receptor agonists could help treat PD more effectively than catechol-based agonists. High throughput screening of about 3 million compounds in an in vitro activity assay...
BC Week In Review | May 11, 2015
Clinical News

Ropinirole: Phase III started

Hisamitsu began a double-blind, Japanese Phase III trial of once-daily transdermal HP-3000 in patients receiving L-dopa. Patients will receive HP-3000 plus an oral placebo; once-daily oral ropinirole extended release plus a transdermal placebo; or a...
BC Week In Review | Feb 17, 2014
Clinical News

Ropinirole: Phase II data

A placebo-controlled, Japanese Phase II trial in PD patients showed that once-daily HP-3000 used concomitantly with levodopa met the primary efficacy endpoint. No adverse events were reported "that would cause major concerns in development." Hisamitsu...
BC Week In Review | Sep 16, 2013
Clinical News

Ropinirole: Phase II started

Hisamitsu began a placebo-controlled, Japanese Phase II trial to evaluate once-daily HP-3000 in patients with moderate to severe idiopathic RLS. Hisamitsu plans to start a Phase III trial of HP-3000 for the fiscal year 2015...
BC Week In Review | Apr 15, 2013
Clinical News

SmithKline regulatory update

The FDA granted marketing approval for Requip ropinirole to treat the signs and symptoms of Parkinson's disease. The product can be used as an initial therapy and as adjunctive treatment with levodopa, the standard treatment....
BC Week In Review | Jul 16, 2012
Clinical News

Titan preclinical data

In a non-human primate model of PD, Titan's subcutaneous ropinirole implant significantly reduced clinical symptoms of PD over several months as measured by Unified Parkinson's Disease Rating Scale (UPDRS) scores vs. controls. Titan also said...
BioCentury | May 7, 2012

Jazz's big band sound

A 2008 decision to concentrate on its commercial business has paid off for Jazz Pharmaceuticals Inc. The company has quadrupled its revenues, reduced its debt and increased its number of marketed drugs tenfold with two...
BioCentury | May 23, 2011

For want of a nail

See Sidebar: Horizons beyond Horizant FDA 's handling of an NDA for Horizant gabapentin enacarbil looked like exactly the kind of thing that provides grist to critics who say the agency is needlessly delaying access...
BC Innovations | Feb 25, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) Dopamine D2 receptor; dopamine D3 receptor Studies in rats identified a hybrid molecule with D2/D3 receptor agonist and iron chelation activities that...
Items per page:
1 - 10 of 68